Related Experiment Video
Updated: Aug 15, 2026
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology
Joshi J Alumkal1, Leigh Ellis2
1University of Michigan Ann Arbor, MI United States.
Summary
Tazemetostat, an EZH2 inhibitor, was withdrawn due to increased risk of second primary malignancies like myelodysplastic syndrome and acute myeloid leukemia. This highlights potential target-driven risks in epigenetic therapy development.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Tazemetostat (Tazverik), an EZH2 inhibitor, was voluntarily withdrawn from all markets in March 2026.
- This withdrawal followed the Phase Ib/III SYMPHONY-1 trial, which revealed an increased incidence of hematologic second primary malignancies (SPMs) in treated patients.
Purpose of the Study:
- To investigate the potential target-driven risks associated with EZH2 inhibition in epigenetic therapies.
- To analyze the biological rationale behind EZH2's dual role as an oncogene and tumor suppressor.
- To propose improvements in preclinical safety assessment, clinical trial design, and pharmacovigilance for epigenetic drugs.
Main Methods:
- Review of clinical trial data (SYMPHONY-1) for tazemetostat.
- Analysis of EZH2 biology, including its role in oncogenesis and normal stem cell function.
- Evaluation of potential risks in ongoing epigenetic therapy development, particularly in prostate cancer.
Main Results:
- The SYMPHONY-1 trial showed SPMs (myelodysplastic syndrome and acute myeloid leukemia) in 5.7% of tazemetostat-treated patients versus none in the control arm.
- EZH2's context-dependent function suggests that chronic inhibition could mimic loss-of-function mutations, potentially initiating myeloid neoplasia.
- Concerns exist for ongoing trials, especially in prostate cancer, due to prolonged exposure risks.
Conclusions:
- The withdrawal of tazemetostat highlights a critical vulnerability in epigenetic therapy development: underestimation of effects on normal stem cell compartments.
- Pharmacologic EZH2 inhibition may pose a broader, target-mediated risk beyond tumor-specific effects.
- Enhanced preclinical safety assessments, adaptive trial designs, and robust pharmacovigilance are crucial for mitigating predictable toxicities of epigenetic therapies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...